Clinical Trials Logo

Clinical Trial Summary

The goal of this observational study is to learn about leakage from retinal vessels in cerebral small vessel disease. The main questions it aims to answer are: - Does retinal vessel leakage occur in cerebral small vessel disease? - If it does, is the severity of retinal vessel leakage similar to the severity of cerebral small vessel disease generally? Participants will be tested using fluorescein angiography. This involves an intravenous injection of fluorescent dye, and is a very sensitive way to find leakage from retinal blood vessels. Participants will have already had brain scans and other examinations and tests to measure the severity of their cerebral small vessel disease. Our new retinal images will complement the information from these previous tests.


Clinical Trial Description

Cerebral small vessel disease (SVD) is a common cause of stroke and dementia. The molecular causes are unclear, limiting new therapies. Breakdown of the blood-brain barrier (BBB) is characteristic and may damage brain tissue. However, specialist MRI scans to measure BBB breakdown are expensive and time-consuming. In contrast, measuring leakage from retinal blood vessels is relatively simple. The blood-retina barrier is very similar to the BBB, and SVD is likely to damage retinal and brain blood vessels in the same way. If so, then retinal angiography could be used to study SVD pathogenesis and measure the effect of new treatments with much greater resolution and lower cost than MRI. We have three aims: 1. Test the feasibility of fluorescein angiography in people with SVD 2. Discover if retinal vessel leakage occurs people with SVD 3. Discover whether the severity of retinal vessel leakage is associated with clinical features of SVD We will recruit participants from a well-established cohort of people with SVD - the Mild Stroke Study 3 (MSS3). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06416371
Study type Observational
Source University of Edinburgh
Contact
Status Not yet recruiting
Phase
Start date September 2024
Completion date July 2025

See also
  Status Clinical Trial Phase
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT04109963 - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment Phase 2
Recruiting NCT04335994 - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing N/A
Completed NCT01761227 - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Phase 2
Active, not recruiting NCT01208675 - The Swedish BioFINDER Study
Completed NCT00165763 - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Phase 4
Completed NCT00621647 - Seroquel- Agitation Associated With Dementia Phase 3
Recruiting NCT04095962 - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia N/A
Recruiting NCT03275363 - The University of Hong Kong Neurocognitive Disorder Cohort N/A
Active, not recruiting NCT03804229 - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Phase 3
Enrolling by invitation NCT03724136 - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study N/A
Completed NCT02453932 - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Phase 3
Completed NCT00947531 - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Phase 4
Not yet recruiting NCT03702543 - Managing Vascular Dementia Risk Factors With SymTrend Phase 1
Enrolling by invitation NCT02147652 - Personalized Music Therapy and Agitation in Dementia N/A
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA
Recruiting NCT06034509 - Cognitive and Vascular Functioning Following TBI
Recruiting NCT05921266 - Urolithin A Supplementation in Middle-aged Adults With Obesity N/A
Not yet recruiting NCT01466543 - Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Phase 2
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A